Sustained effectiveness and safety of esketamine for major depressive disorder: a target trial simulation of real-world data.
Abstract
This study aimed to evaluate the long-term effectiveness and safety of esketamine in adults with Major depressive disorder (MDD), focusing on suicide-related events, all-cause mortality, and major adverse cardiovascular events (MACEs). This target-trial simulation used the TriNetX Global Collaborative Network. Adults (≥ 18 years) with MDD who received either esketamine or a conventional antidepressant during an inpatient episode were included. After propensity-score matching for demographic and clinical variables, matched pairs were analyzed followed up to 2 years. The primary outcome was a composite of suicide-related events. Hazard ratios (HRs) with 95% CIs were estimated across acute (days 1-14), intermediate (days 15-365), and long-term (days 15-730) periods. After 1:1 matching, 3383 pairs were analyzed. Esketamine use was associated with lower suicide-related events at days 1-14 (0.77% vs 3.78%; HR, 0.19; 95% CI, 0.12-0.29; P < 0.001), days 15-365 (2.13% vs 2.63%; HR, 0.63; 95% CI, 0.46-0.86; P = 0.003), and days 15-730 (2.66% vs 2.78%; HR, 0.74; 95% CI, 0.55-0.99; P = 0.04). Mortality was lower (6.03% vs 7.63%; HR, 0.61; 95% CI, 0.51-0.73; P < 0.001), as was recurrent MDD at 2 years (3.46% vs 4.67%; HR, 0.76; 95% CI, 0.59-0.98; P = 0.04). MACEs were lower during days 1-14 (2.10% vs 4.97%; HR, 0.39; 95% CI, 0.30-0.51; P < 0.001) and not significantly different thereafter. In conclusion, esketamine treatment was associated with sustained reductions in suicidal ideation and all-cause mortality without increased MACEs risk. The composite suicide-related outcome was primarily driven by reductions in suicidal ideation; differences in suicide attempt and intentional self-harm could not be determined due to low event counts.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.